10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2014 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 12, 2015) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Cash flows from operating activities: | |||
| Net income | $ 348,074 | 424,362 | 750,269 |
| Adjustments to reconcile net income to net cash provided by (used in) operating activities: | |||
| Depreciation and amortization | 52,686 | 41,204 | 36,940 |
| Non-cash compensation expense | 307,238 | 198,399 | 94,157 |
| Non-cash interest expense | 18,052 | 23,061 | 22,925 |
| Loss on Extinguishment of Debt | 33,469 | 0 | 0 |
| Other non-cash charges and expenses, net | 30,003 | 23,690 | 34,049 |
| Increase (Decrease) in Deferred Income Taxes | (66,604) | 63,601 | (340,156) |
| Changes in assets and liabilites | |||
| Increase in Sanofi, Bayer HealthCare, and trade accounts receivable | (62,432) | (258,994) | (588,398) |
| Increase in Inventories | (60,900) | (47,956) | (28,932) |
| (Increase) decrease in prepaid expenses and other assets | (37,767) | 7,571 | (25,371) |
| Increase (decrease) in deferred revenue | 19,102 | (27,974) | (41,077) |
| Increase in accounts payable, accrued expenses and other liabilities | 162,236 | 136,684 | 10,979 |
| Total adjustments | 395,083 | 159,286 | (824,884) |
| Net cash provided by (used in) operating activities | 743,157 | 583,648 | (74,615) |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (564,188) | (577,278) | (470,945) |
| Sales or maturities of marketable securities | 476,417 | 378,146 | 439,209 |
| Capital expenditures | (333,006) | (156,323) | (49,337) |
| Net cash used in by investing activities | (420,777) | (355,455) | (81,073) |
| Cash flows from financing activities: | |||
| Payments in connection with facility and capital lease obligations | (1,095) | (2,024) | (2,203) |
| Repayments of convertible senior debt | (220,639) | 0 | 0 |
| Payments in connection with reduction of outstanding warrants | (294,552) | 0 | 0 |
| Proceeds from issuance of Common Stock | 126,045 | 57,393 | 63,549 |
| Payments in connection with Common Stock tendered for employee tax obligations | (267,584) | (195,087) | (163,300) |
| Excess tax benefit from stock-based compensation | 448,556 | 216,857 | 4,308 |
| Net cash (used in) provided by financing activities | (209,269) | 77,139 | (97,646) |
| Net increase (decrease) in cash and cash equivalents | 113,111 | 305,332 | (253,334) |
| Cash and cash equivalents at beginning of period | 535,608 | 230,276 | |
| Cash and cash equivalents at end of period | 648,719 | 535,608 | 230,276 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest (net of amounts capitalized) | 20,614 | 23,842 | 21,946 |
| Cash paid for income taxes | 59,847 | 1,057 | 0 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |